1.642USD-16.21%Mkt Cap: 102.95M USDP/E: —Last update: 2026-05-26
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consist…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap102.95M USD
Enterprise Value100.37M USD
Revenue (TTM)13.86M USD
Gross Profit11.47M USD
Net Income (TTM)-79.62M USD
Revenue/Share0.2210 USD
Last Price1.642 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees56
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.58
PEG—
EV/EBITDA-1.28
EV/Revenue7.24
P/S8.87
P/B2.28
EPS (TTM)-1.30
EPS (Forward)-1.23
52W Range
0.970015% of range5.550
52W High5.550 USD
52W Low0.9700 USD
Profitability
Gross Margin82.77%
Oper. Margin-600.20%
EBITDA Margin0.00%
Profit Margin-574.55%
ROE-149.08%
ROA-87.00%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-63.50M USD
CapEx (TTM)9.00K USD
FCF Margin—
FCF Yield—
Net Debt-22.76M USD
Net Debt/EBITDA0.29
Balance Sheet
Debt/Equity0.35
Current Ratio2.76
Quick Ratio2.48
Book Value/Sh0.8520 USD
Cash/Share0.6460 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)6.889 USD
Target Range5.000 USD – 9.000 USD
# Analysts9
Ownership
Shares Out.63.36M
Float40.61M
Insiders22.13%
Institutions33.84%
Short Interest
Short Ratio5.3d
Short % Float4.29%
Short % Out.3.16%
Shares Short1.99M
Short (prev mo.)2.66M
Technical
SMA 501.766 (-7.0%)
SMA 2002.243 (-26.8%)
Beta1.43
S&P 52W Chg28.31%
Avg Vol (30d)608.48K
Avg Vol (10d)718.55K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—